Orchard Therapeutics plc

(NASDAQ:ORTX)

Latest On Orchard Therapeutics plc (ORTX):

Date/Time Type Description Signal Details
2023-05-19 19:49 ESTNewsOrchard Therapeutics updates gene therapy data in metabolic disordersN/A
2023-05-15 19:19 ESTNewsOrchard Therapeutics GAAP EPS of -$0.12, revenue of $1.23MN/A
2023-04-25 01:40 ESTNewsOrchard Therapeutics: MLD Opportunity Could Be Larger Than Initial EstimatesN/A
2023-03-28 16:56 ESTNewsOrchard Therapeutics (ORTX) Investor Presentation - Slideshow'N/A
2023-03-10 18:33 ESTNewsOrchard Therapeutics plc (ORTX) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 09:18 ESTNewsOrchard Therapeutics announces up to $188M strategic financingN/A
2023-03-06 09:18 ESTNewsOrchard Therapeutics GAAP EPS of -$0.06 beats by $0.15, revenue of $6.97M beats by $1.66MN/A
2023-02-10 22:44 ESTNewsOrchard Therapeutics announces 1-for-10 ADS ratio changeN/A
2023-01-05 18:29 ESTNewsOrchard adds ~32% as FDA clears trial for metabolic disorder drugN/A
2022-12-20 23:44 ESTNewsOrchard Therapeutics: Growing A Position In This Undervalued Gene Therapy PlayN/A
2022-12-01 23:31 ESTNewsOrchard's Libmeldy for rare disorder gets Swissmedic reviewN/A
2022-11-14 20:39 ESTNewsOrchard Therapeutics GAAP EPS of -$0.37 misses by $0.13, revenue of $5.78M beats by $1.37MN/A
2022-11-14 20:39 ESTNewsOrchard Therapeutics plc 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-14 20:39 ESTNewsOrchard Therapeutics plc (ORTX) Q3 2022 Earnings Call TranscriptN/A
2022-11-11 23:09 ESTNewsOrchard Therapeutics Q3 2022 Earnings PreviewN/A
2022-08-21 03:35 ESTNewsOrchard Therapeutics: Gene Therapy For Rare Child DiseaseN/A
2022-08-16 02:39 ESTNewsTemasek boosts Amazon stake, exits Starbucks and SalesforceN/A
2022-08-04 21:54 ESTNewsOrchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19MN/A
2022-06-12 08:33 ESTNewsWith bluebird bio's success, what are other gene therapies companies to pay attention to?N/A
2022-05-13 05:36 ESTNewsOrchard Therapeutics PLC (ORTX) CEO Bobby Gaspar on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 10:21 ESTNewsOrchard Therapeutics GAAP EPS of -$0.35 misses by $0.10, revenue of $5.52M beats by $1.48MN/A
2022-05-11 16:53 ESTNewsOrchard Therapeutics Q1 2022 Earnings PreviewN/A
2022-03-30 12:37 ESTNewsOrchard to cut ~30% workforce amid plans to refine portfolio; reports Q4 resultsN/A
2022-03-30 12:37 ESTNewsOrchard Therapeutics' (ORTX) CEO Bobby Gaspar on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-04 15:08 ESTNewsOrchard wins reimbursement for stem cell gene therapy in U.K.N/A
2022-01-21 21:34 ESTNewsOrchard reports long term benefit of gene therapy Libmeldy for rare disorderN/A
2022-01-20 14:16 ESTNewsOrchard Therapeutics: Shadow Of Former GloryN/A
2021-12-29 13:56 ESTNewsOrchard Therapeutics assumed Overweight at Cantor with $9 targetN/A
2021-11-10 00:07 ESTNewsWarning: ORTX is at high risk of performing badlyN/A
2021-11-04 22:48 ESTNewsOrchard Therapeutics EPS misses by $0.04, misses on revenueN/A
2021-09-27 10:05 ESTNewsOrchard Therapeutics (ORTX) Investor Prentation - SlideshowN/A
2021-09-22 17:30 ESTNewsOxford Biomedica plc reports 1H resultsN/A
2021-08-16 11:30 ESTNewsOrchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical HurdlesN/A
2021-08-04 21:27 ESTNewsOrchard Therapeutics EPS beats by $0.04N/A
2021-07-22 15:59 ESTNewsOrchard Therapeutics updates on gene therapy programsN/A
2021-07-22 15:58 ESTNewsOrchard Therapeutics draws a lower price target at Cantor on delayed milestonesN/A
2021-07-22 15:58 ESTNewsOrchard Therapeutics inks strategic deal to develop HSC gene therapy for hereditary angioedemaN/A
2021-03-25 07:11 ESTNewsOrchard Therapeutics: Curative Medicines For Immune-Related DiseasesN/A
2021-03-11 20:48 ESTNewsOrchard Therapeutics: Slow And Steady, But Lacking Major Near-Term CatalystsN/A
2021-03-11 00:49 ESTNewsBluebird bio upgraded to buy at Mizuho on safety updateN/A
2021-03-05 02:28 ESTAnalyst RatingThe Analyst Target Price has increased from $14.89 to $15.11.Buy
2021-03-04 17:45 ESTFinancialsCompany financials have been released.Neutral
2021-03-03 20:02 ESTNewsOrchard expands Be The Match Bio collaboration ahead of Libmeldy launchN/A
2021-03-03 10:03 ESTEarnings EstimateAn EPS average of -$1.14 is estimated for the 2022 year.Sell
2021-03-03 10:03 ESTEarnings EstimateAn EPS average of -$0.36 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-03 10:03 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.11 to $14.89.Neutral
2021-02-18 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.67 to $15.11.Buy
2021-02-16 21:39 ESTNewsBluebird bio trial suspension hurts Orchard and AVROBION/A
2021-02-11 22:20 ESTAnalyst RatingThe Analyst Target Price has increased from $13.78 to $14.67.Buy
2021-02-11 00:51 ESTNewsOrchard Therapeutics announces interim data for OTL-203 in mucopolysaccharidosisN/A

About Orchard Therapeutics plc (ORTX):

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

ORTX Quotes by TradingView

See Advanced Chart

General

  • Name Orchard Therapeutics plc
  • Symbol ORTX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 224
  • Fiscal Year EndDecember
  • IPO Date2018-10-31
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.orchard-tx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 328.42
  • Price/Book (Most Recent Quarter) 5.94
  • Enterprise Value Revenue 356.95
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.31
  • Next Year EPS Estimate -$1.05
  • Next Quarter EPS Estimate -$0.36
  • Operating Margin -5558%
  • Return on Assets -27%
  • Return on Equity -64%
  • Revenue 2.6 million
  • Earnings Per Share -$2.27
  • Revenue Per Share $0.03
  • Gross Profit 1.74 million
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 1 billion
  • EBITDA -143886000
  • Analyst Target Price $15.11
  • Book Value Per Share $1.82
View More

Share Statistics

  • Shares Outstanding 123.7 million
  • Shares Float 84.94 million
  • % Held by Insiders 23%
  • % Held by Institutions 67.39%
  • Shares Short 5.25 million
  • Shares Short Prior Month 4.12 million
  • Short Ratio 2.1
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.23
  • 52 Week High $12.38
  • 52 Week Low $3.76
  • 50 Day Moving Average 7.35
  • 200 Day Moving Average 5.52
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Orchard Therapeutics plc (ORTX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Orchard Therapeutics plc (ORTX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$N/A-$0.34-$0.29-18.18%
2020-09-302020-11-03$2 million-$0.20-$0.4049.53%
2020-06-302020-08-06$N/A-$0.42-$0.41-3.53%
2020-03-312020-05-07$N/A-$0.51-$0.50-2.41%
2019-12-312020-02-27$595000-$0.46-$0.43-7.85%
2019-09-302019-11-06$1.92 million-$0.38-$0.418.37%
2019-06-302019-08-08$N/A-$0.56-$0.34-63.84%
2019-03-312019-05-28$N/A-$0.35-$0.4827.54%
2018-12-312019-03-21$1.04 million-$0.35-$0.4928.57%

Orchard Therapeutics plc (ORTX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Orchard Therapeutics plc (ORTX) Chart:

Orchard Therapeutics plc (ORTX) News:

Below you will find a list of latest news for Orchard Therapeutics plc (ORTX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Orchard Therapeutics plc (ORTX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ORTX Trades:

Date Shares Price
Jun 13, 2022 7:52 PM EST25$0.5625
Jun 13, 2022 7:52 PM EST200$0.561
Jun 13, 2022 7:52 PM EST300$0.561
Jun 13, 2022 7:52 PM EST24$0.56
Jun 13, 2022 7:55 PM EST100$0.5616

Orchard Therapeutics plc (ORTX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037926/0001209191-20-037926-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1748907/000008025520001367/0000080255-20-001367-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000031506620000001/0000315066-20-000001-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000031506620000002/0000315066-20-000002-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1748907/000031506620000757/0000315066-20-000757-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1748907/000110465920021899/0001104659-20-021899-index.htm
2020-04-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1748907/000110465920045219/0001104659-20-045219-index.htm
2020-11-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000110465920122532/0001104659-20-122532-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000110465920122542/0001104659-20-122542-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1748907/000119312520027690/0001193125-20-027690-index.htm
2020-02-28POSASRPost-effective Amendment to an automatic shelf registration statementhttps://www.sec.gov/Archives/edgar/data/1748907/000119312520053354/0001193125-20-053354-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000119312520080654/0001193125-20-080654-index.htm
2020-04-14PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1748907/000119312520107148/0001193125-20-107148-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1748907/000119312520126076/0001193125-20-126076-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1748907/000119312520211883/0001193125-20-211883-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1748907/000119380520000200/0001193805-20-000200-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000274/0001209191-20-000274-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000277/0001209191-20-000277-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000279/0001209191-20-000279-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000281/0001209191-20-000281-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000283/0001209191-20-000283-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000285/0001209191-20-000285-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000287/0001209191-20-000287-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000290/0001209191-20-000290-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000293/0001209191-20-000293-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120000295/0001209191-20-000295-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120001784/0001209191-20-001784-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120001811/0001209191-20-001811-index.htm
2020-02-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120006154/0001209191-20-006154-index.htm
2020-02-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120006159/0001209191-20-006159-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120016235/0001209191-20-016235-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120023123/0001209191-20-023123-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120023125/0001209191-20-023125-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120036661/0001209191-20-036661-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037901/0001209191-20-037901-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037904/0001209191-20-037904-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037907/0001209191-20-037907-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037909/0001209191-20-037909-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037911/0001209191-20-037911-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037918/0001209191-20-037918-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000120919120037926/0001209191-20-037926-index.htm
2020-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1748907/000138713120000048/0001387131-20-000048-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1748907/000156459019041006/0001564590-19-041006-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1748907/000156459019041351/0001564590-19-041351-index.htm
2019-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1748907/000156459019043217/0001564590-19-043217-index.htm
2019-11-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1748907/000156459019043762/0001564590-19-043762-index.htm
2019-12-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1748907/000156459019045032/0001564590-19-045032-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020000869/0001564590-20-000869-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020002373/0001564590-20-002373-index.htm
2020-02-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020002991/0001564590-20-002991-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020007015/0001564590-20-007015-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1748907/000156459020007353/0001564590-20-007353-index.htm
2020-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020014535/0001564590-20-014535-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020018675/0001564590-20-018675-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020022353/0001564590-20-022353-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1748907/000156459020022822/0001564590-20-022822-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020025616/0001564590-20-025616-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020029938/0001564590-20-029938-index.htm
2020-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020032077/0001564590-20-032077-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020032389/0001564590-20-032389-index.htm
2020-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020032669/0001564590-20-032669-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020037230/0001564590-20-037230-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1748907/000156459020037239/0001564590-20-037239-index.htm
2020-09-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020042073/0001564590-20-042073-index.htm
2020-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020044744/0001564590-20-044744-index.htm
2020-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020046580/0001564590-20-046580-index.htm
2020-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020049338/0001564590-20-049338-index.htm
2020-11-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020049768/0001564590-20-049768-index.htm
2020-11-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1748907/000156459020049771/0001564590-20-049771-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1748907/000156459020050847/0001564590-20-050847-index.htm

Orchard Therapeutics plc (ORTX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Orchard Therapeutics plc (ORTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 23%
Institutional Ownership: 6739%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-06-11FRANK E THOMASOfficerBuy10,000.002.4424,400.0025,120.00https://www.sec.gov/Archives/edgar/data/1748907/000120919120036661/0001209191-20-036661-index.htm
2020-03-02Bobby GasparOfficerSell4,921.0013.0063,973.00348,319.00https://www.sec.gov/Archives/edgar/data/1748907/000120919120016235/0001209191-20-016235-index.htm
2020-03-02Bobby GasparOfficerBuy4,921.000.000.49353,240.00https://www.sec.gov/Archives/edgar/data/1748907/000120919120016235/0001209191-20-016235-index.htm
2020-01-02FMR LLC10% Share HolderSell8,753.0013.41117,377.736,122,295.00https://www.sec.gov/Archives/edgar/data/1748907/000031506620000002/0000315066-20-000002-index.htm
2020-01-02FMR LLC10% Share HolderSell5,484.0013.5574,308.206,131,048.00https://www.sec.gov/Archives/edgar/data/1748907/000031506620000002/0000315066-20-000002-index.htm